XML 61 R6.htm IDEA: XBRL DOCUMENT v3.19.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 6 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (2,493,821) $ (1,827,419) $ (3,257,597) $ (3,901,232)
Adjustments to reconcile net loss to net cash (used in) operating activities        
Depreciation and amortization 133,019 30,462 132,615 81,283
Issuance of capital stock for services and expenses 348,900 70,641 440,319 547,838
Stock based compensation- warrants 336,835 0    
Conversion of interest 0 64,233 64,233 68,043
Stock based compensation- stock option grants 263,147 7,334 50,899 37,848
(Loss) on sale of assets     0 113,244
Loss on change - derivative liability     0 (145,282)
Reclassification of derivative liability     0 410,324
Amortization of debt discount 0 475,174 475,174 158,941
Conversion of accrued liabilites- related parties to convertible notes payable 0 491,802 491,802 0
Provision on loss on accounts receivable 8,728 21,406 10,747 0
Stock based compensation- warrants     239,680 5,000
Issuance of common stock for conversion of liabilities     199,935 0
Non-cash gain on accounts payable     (170,309) 0
Impairment of goodwill 0 110,545 0 983,645
Bad debt expense     0 136,217
Changes in operating assets and liabilities:        
Accounts receivable 118,438 114,918 362,035 (20,582)
Prepaid expenses 7,296 4,292 7,547 (7,204)
Inventory 102,593 21,616 22,327 69,309
Other assets (8,697) (2,100) (2,100) 0
Accounts payable - trade and accrued expenses (223,216) 33,193 (176,495) 134,382
Deferred revenue (55,959) (58,615) (7,943) 63,902
NET CASH (USED IN) OPERATING ACTIVITIES (1,462,737) (442,518) (1,117,131) (1,264,324)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Investment in research and development equipment (74,556) 0    
Investment in BioMedx, Inc., net     0 (260,000)
Proceeds from investment in BioMedx, Inc,     0 290,000
Capital expenditures     (97,251) 2,441
Proceeds from sale of equipment     0 1,434
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES: (74,556) 0 (97,251) 33,875
CASH FLOWS FROM FINANCING ACTIVITIES:        
(Repayments) proceeds from line of credit (145,188) (190,663) (220,539) 30,321
Proceeds from convertible notes payable 0 530,000 636,000 690,000
Proceeds from issuance of common/preferred stock, net of costs 3,809,975 0 1,750,000 550,000
Issuance of common stock for warrant exercise     80,147 0
Repayment of convertible notes     0 (125,000)
Repayment of note payable     (200,000) 0
NET CASH PROVIDED BY FINANCING ACTIVITIES 3,664,787 339,337 2,045,608 1,145,321
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,127,494 (103,181) 831,226 (85,128)
CASH AND CASH EQUIVALENTS, beginning of period 934,407 103,181 103,181 188,309
CASH AND CASH EQUIVALENTS, end of period 3,061,901 0 934,407 103,181
Supplemental disclosures of cash flow information:        
Interest paid 7,750 20,243 64,228 47,789
Taxes paid 0 0 0 0
Non-cash investing and financing activities:        
Beneficial conversion feature 0 482,014 348,096 0
Conversion of convertible debt $ 0 $ 482,014 0 695,000
Beneficial conversion feature     0 559,130
Conversion of convertible debt to preferred shares     0 220,000
Related party accounts converted to notes     1,184,066 0
Acquisition of patents     520,000 0
Penalty on notes payable     $ 75,000 $ 0